Publicación:
Management of Neuroendocrine Tumors: A Meeting of Experts from Latin America

Vista sencilla de ítem
dc.contributor.authorCosta, F.
dc.contributor.authorDomenichini, E.
dc.contributor.authorGaravito, G.
dc.contributor.authorMedrano, R.
dc.contributor.authorMendez, G.
dc.contributor.authorO’Connor, J.
dc.contributor.authorRojas, W.
dc.contributor.authorTorres, S.
dc.contributor.authorYounes, R.N.
dc.contributor.authorDelle Fave, G.
dc.contributor.authorÖberg, K.
dc.date.accessioned2021-04-15T16:42:24Z
dc.date.available2021-04-15T16:42:24Z
dc.date.issued2008
dc.description.abstractA panel of experts from Latin America convened in Brazil, in May of 2007, for consensus recommendations regarding the management of neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas. The recently introduced World Health Organization classification of NETs represents a step forward, but the former classification of carcinoids into foregut, midgut and hindgut is still likely to be useful in the near future. Macroscopic description of the tumor should be followed by light microscopic examination and immunohistochemical staining, whereas other techniques might not be widely available in Latin America. Surgery remains the mainstay of treatment for patients with potentially curable tumors, and adequate selection is paramount in order to optimize treatment results. Regarding systemic therapy, patients with well-differentiated tumors or islet-cell carcinomas may be categorized as having indolent disease, while patients with poorly differentiated, anaplastic, and small-cell carcinomas, or with atypical carcinoids, may be approached initially as having aggressive disease. Somatostatin analogues play a cytostatic role in indolent tumors, and chemotherapy may play a role against other, more aggressive NETs. Obviously, there is an urgent need for novel therapies that are effective against NETs.eng
dc.format.extent8 p.spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.1159/000149356
dc.identifier.urihttps://repositorio.fucsalud.edu.co/handle/001/1426
dc.language.isoengspa
dc.publisherClinical Neuroendocrinology and Neuroendocrine Tumorsspa
dc.relation.citationendpage242spa
dc.relation.citationstartpage235spa
dc.relation.citationvolume88spa
dc.relation.ispartofNeuroendocrinology Vol. 88 (2008)
dc.relation.ispartofjournalNeuroendocrinologyspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/spa
dc.sourcehttps://www.karger.com/Article/Abstract/149356spa
dc.subject.decsInterferones
dc.subject.decsTumores neuroendocrinos
dc.subject.decsOctreótido
dc.subject.proposalInterferoneng
dc.subject.proposalLatin Americaeng
dc.subject.proposalNeuroendocrine tumorseng
dc.subject.proposalOctreotideeng
dc.subject.proposalRadionuclide imagingeng
dc.subject.proposalSomatostatin receptorseng
dc.titleManagement of Neuroendocrine Tumors: A Meeting of Experts from Latin Americaeng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Management of Neuroendocrine Tumors-1.pdf
Tamaño:
60.21 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
15.06 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos